- Global Pharma News & Resources

Destiny Pharma notes release of UK Government’s Vision and 5-year action plan to help tackle anti-microbial resistance (AMR), which includes additional investment in innovation

Government’s plan consistent with Destiny Pharma’s objective of developing novel anti-infectives from its proprietary XF platform.

Brighton, United Kingdom – 24 January 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of anti-microbial resistance (AMR), notes the publication of the UK Government’s 20-year vision and 5-year action plan on AMR which outlines how the government will contribute to the global effort against AMR through optimising use of antimicrobials and investing in innovation, supply and access.

Neil Clark, Chief Executive Officer of Destiny Pharma commented:

“Destiny Pharma welcomes the UK government’s announcements today that highlight the UK and global concern about the continuing threat to human health from AMR and the lack of new, innovative approaches to preventing and treating bacterial infections. Destiny Pharma also welcomes government recognition of the need for financial support for companies carrying out research and drug development for anti-infectives that address AMR and new financial incentives for pharmaceutical companies that distribute and sell anti-infective drugs.”

Destiny Pharma’s strategy is set out to meet the challenge outlined in the UK’s 5-year action plan, with its XF platform being developed to deliver novel anti-infective drugs that specifically address the global challenge of AMR. Its lead programme, XF-73, is in clinical studies for the prevention of costly, post-surgical infections such as Methicillin-resistant Staphylococcus aureus (MRSA).  Unlike most antibiotics, XF-73 has not been seen to generate bacterial resistance in industry-standard microbiology tests to date and therefore also has significant potential to address the global threat of AMR alongside its fast, safe and effective anti-infective action.

Find out more about the UK’s plans to see AMR contained and controlled by 2040 via the two links below:


For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

Editor Details

Last Updated: 25-Jan-2019